A Phase 1b Trial of Selinexor Plus Doxorubicin in Advanced Soft Tissue Sarcomas (STS)
Phase of Trial: Phase I
Latest Information Update: 05 Jun 2017
At a glance
- Drugs Selinexor (Primary) ; Doxorubicin
- Indications Soft tissue sarcoma
- Focus Adverse reactions
- 29 May 2017 Planned End Date changed from 27 Sep 2020 to 16 Nov 2020.
- 29 May 2017 Planned primary completion date changed from 27 Mar 2020 to 16 May 2020.
- 29 May 2017 Status changed from not yet recruiting to recruiting.